尊龙凯时人生就是搏·(中国区)官方网站

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR PHASE II CLINICAL TRIAL ON LM-24C5 "CEACAM5/4-1BB BISPECIFIC ANTIBODY" APPROVED BY THE NMPA

VOLUNTARY ANNOUNCEMENT - ROVADICITINIB TABLET "JAK/ROCK INHIBITOR" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINCAL TRIAL OF TQC3302 "ICS/LAMA/LABA SOFT MIST INHALATION FORMULATION" APPROVED BY NMPA

NOTIFICATION OF BOARD MEETING

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2025

VOLUNTARY ANNOUNCEMENT - LM-299 OUT-LICENSING COLLABORATION PROGRESSING SMOOTHLY; US$300 MILLION MILESTONE PAYMENT TO BE RECEIVED SHORTLY

VOLUNTARY ANNOUNCEMENT - IND APPROVAL FOR LM-350 "CDH17 ADC" FROM THE US FDA

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION FULL ACQUISITION OF LANOVA MEDICINES